Arvinas, Inc. (ARVN)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Arvinas, Inc. (ARVN)
Company Performance

Current Price

as of Oct 16, 2024

$27.80

P/E Ratio

N/A

Market Cap

$1.91B

Description

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

Metrics

Overview

  • HQNew Haven, CT
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerARVN
  • Price$27.8+7.34%

Trading Information

  • Market Cap$1.91B
  • Float86.58%
  • Average Daily Volume (1m)551,657
  • Average Daily Volume (3m)591,640
  • EPS-$5.17

Company

  • Revenue$93.30M
  • Rev Growth (1yr)40.37%
  • Net Income-$35.20M
  • Gross Margin97.78%
  • EBITDA Margin-61.18%
  • EBITDA-$46.80M
  • EV$682.08M
  • EV/Revenue7.31
  • P/EN/A
  • P/S21.42
  • P/B3.18
Documents
SEC Filings
8-K (2024-08-20)
8-K (2024-07-30)
8-K (2024-06-24)
8-K (2024-06-18)
8-K (2024-06-17)
8-K (2024-05-30)
8-K (2024-05-16)
8-K (2024-05-07)
8-K (2024-04-11)
8-K (2024-03-18)
8-K (2024-02-27)
8-K (2024-02-20)
8-K (2024-01-08)
8-K (2023-12-06)
8-K (2023-11-27)
8-K (2023-11-07)
8-K (2023-10-23)
8-K (2023-08-08)
8-K (2023-06-21)
8-K (2023-06-08)
8-K (2023-05-05)
8-K (2023-03-10)
8-K (2023-02-23)
8-K (2023-01-09)
10-Q (2024-07-30)
10-Q (2024-05-07)
10-Q (2023-11-07)
10-Q (2023-08-08)
10-Q (2023-05-05)
10-K (2024-02-27)
10-K (2023-02-23)
Factset Street Account
Potential of Arvinas' PROTAC AR degraders reinforced by 11.1 months rPFS with bavdegalutamide and updated positive interim data from second generation ARV-766 in mCRPC ($14.83, 0.00) (2023-10-22T14:13:21Z)
Arvinas upgraded to outperform from neutral at Wedbush Securities (pre-open) ($14.98, +0.15) (2023-10-23T15:28:32Z)
Arvinas upgraded to buy from neutral at Guggenheim Securities ($20.92, 0.00) (2023-11-20T11:13:35Z)
Arvinas reports Q3 EPS ($1.18) vs FactSet ($1.58) [17 est, ($2.03)-(1.10)] ($16.93, 0.00) (2023-11-07T12:09:36Z)
Arvinas announces oversubscribed $350M private placement of common stock and pre-funded warrants through BofA Securities and Goldman Sachs ($21.87, 0.00) (2023-11-27T12:03:23Z)
Factset
Factset Business Description